The global endometrial cancer treatment market is expected to witness growth due to unmet need of treatment, technological advancement in cancer therapeutics and diagnostic test, rising prevalence of cancer, and sedentary lifestyle of women. In addition, increasing awareness about the uterine diseases and the available therapies and increasing healthcare expenditure is also driving the growth of global endometrial cancer treatment market.
Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/report-sample
The pharmaceutical companies are actively involved in the endometrial cancer research and development. AEterna Zentaris, Inc., is developing Zoptrex (zoptarelin doxorubicin), a Phase III clinical trial drug candidate for the treatment of endometrial cancer. In October 2016, the company entered into licensing agreement with Specialized Therapeutics Asia, a biopharmaceutical company, for the marketing of zoptarelin doxorubicin in Australia and New Zealand.
Certain factors such as high treatment cost, low success rate of clinical trials, side effects of the treatment, high research and development expenditure, and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.
Explore Full Report at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market
Some of the key players operating in the global market are Bristol-Myers Squibb Company, Merck & Co., Inc., Ariad Pharmaceuticals Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories.